Ieq Capital LLC Acquires Shares of 15,453 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Ieq Capital LLC acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 15,453 shares of the company’s stock, valued at approximately $291,000.

A number of other hedge funds also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its holdings in Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after purchasing an additional 918 shares during the period. Caitlin John LLC increased its stake in shares of Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after buying an additional 1,776 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after buying an additional 2,749 shares during the period. Quest Partners LLC increased its stake in shares of Pacira BioSciences by 137.6% during the third quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock valued at $142,000 after buying an additional 5,449 shares during the period. Finally, Virtus Investment Advisers Inc. purchased a new position in Pacira BioSciences during the 3rd quarter valued at $98,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on PCRX shares. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada reiterated a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Barclays upped their target price on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday. Needham & Company LLC upped their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday. Finally, HC Wainwright upped their price target on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Trading Down 5.2 %

NASDAQ PCRX opened at $24.05 on Friday. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $31.67. The stock has a market cap of $1.11 billion, a P/E ratio of -11.85 and a beta of 0.80. The stock’s fifty day moving average price is $23.16 and its 200-day moving average price is $18.58. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.